
Sign up to save your podcasts
Or


Join Dr. Paul Kolodzik on The Second Opinion as he discusses the recent significant price drop in name-brand GLP-1 medications. In this episode, he explores the reasons behind the price reduction, what it means for patients and healthcare providers, and how this change could impact diabetes management and weight loss treatments. Tune in for expert insights and a deep dive into the factors shaping this now more accessible medication market.
By DR. Paul Kolodzik3.3
66 ratings
Join Dr. Paul Kolodzik on The Second Opinion as he discusses the recent significant price drop in name-brand GLP-1 medications. In this episode, he explores the reasons behind the price reduction, what it means for patients and healthcare providers, and how this change could impact diabetes management and weight loss treatments. Tune in for expert insights and a deep dive into the factors shaping this now more accessible medication market.

1,732 Listeners

4,925 Listeners

8,723 Listeners

337 Listeners

1,116 Listeners

460 Listeners

231 Listeners

3,509 Listeners

21,452 Listeners

1,292 Listeners

218 Listeners

3,201 Listeners